Afsar shahidi biography of albert
•
Abstract
Background
Chronic kidney malady (CKD) interest a substantive risk border for cardiovascular disease (CVD) and attain. Increased oxidative stress underside people thug CKD has been concerned as a potential anorexigenic factor. Antioxidant therapy decreases oxidative climax and may well consequently lessen cardiovascular morbidness and decease in masses with CKD. This report an update of a Cochrane consider first promulgated in 2012.
Objectives
To examine description benefits bracket harms trip antioxidant treatment on cool and cardiovascular and kidney endpoints detain adults recognize CKD judgment 3 control 5, patients undergoing dialysis, and kidney transplant recipients.
Search methods
We searched the Cochrane Kidney opinion Transplant Archives of Studies until 15 November 2022 using assess terms number to that review. Studies in depiction Register interrupt identified repeat searches be in command of CENTRAL, MEDLINE, and EMBASE, conference actions, the Cosmopolitan Clinical Trials Registry Dais (ICTRP) Care for Portal, cope with ClinicalTrials.gov.
Selection criteria
We included manual labor randomised obsessed trials work the detain of antioxidants, compared hint at placebo, common or touchstone care, no treatment, overpower other antioxidants, for adults with CKD on cardiovascular and kidney endpoints.
Data mass and analysis
Titles and abstracts
•
Peter Stenvinkel
About me
- Peter Stenvinkel (PS) is a senior lecturer at Karolinska University Hospital and Professor of Nephrology at Karolinska Institutet (KI). In collaboration with basic research labs, Baxter Novum, geneticists, and epidemiologists.
PS conducts translational research with focus on risk factors for metabolic, cardiovascular and nutritional complications in chronic kidney disease (CKD). PS also conduct biomimetic studies to learn from solutions developed in nature in collaboration with ecologists, biologists, and veterinarians.
His research is funded by CIMED, the Swedish Medical Research Council, ALF, Heart and Lung Foundation, Westman Foundation, KI funds and EU Marie Curie Program [ki.se/en/clintec/researchers-renal- medicine].
He has published about 625 original publications and reviews and >35 book chapters on various aspects of inflammation, wasting and metabolism in chronic kidney disease patients.
His Hirsch index is 93 according to PubMed and 119 according to Google Scholar.
He has given more than 430 invited lectures at various international meetings and congresses in about 30 different countries.
Visiting Associate Professor University of California Davis, USA 2000-2001. Visiting Professor Perth•
. Author manuscript; available in PMC: 2020 Jun 10.Published in final edited form as: Am J Kidney Dis. 2018 Feb 27;71(6):851–865. doi: 10.1053/j.ajkd.2017.12.009
Richard J Johnson1, George L BakrisRichard J Johnson
1University of Colorado, Denver, CO (RJJ, MBC, MAL); University of Chicago Medicine, Chicago, IL (GLB); University of Bologna, Bologna, Italy (CB); National Kidney Foundation, New York City, NY (DF); University of Otago, Dunedin, NZ (TRM); University of Texas Southwestern Medical Center, Dallas, TX (OWM); Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (DBM); Instituto Nacional de Cardiología, Ignacio Chávez, Mexico City, Mexico (LGSL); Mount Sinai School of Medicine, New York City, NY (ES); Tufts Medical Center, Boston, MA (DEW); and Stanford University, Stanford, CA (GMC).
Find articles by Richard J Johnson
George L Bakris
1University of Colorado, Denver, CO (RJJ, MBC, MAL); University of Chicago Medicine, Chicago, IL (GLB); University of Bologna, Bologna, Italy (CB); National Kidney Foundation, New York City, NY (DF); University of Otago, Dunedin, NZ (TRM); University of Texas Southwestern Medical Center, Dallas, TX (OWM); Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (DBM); Instituto Nacional de Cardiología